Company: GHRS
Filing Date: 2025-02-27
Form Type: 20-F
Source: 0001140361-25-006175
Chunk: 86

Company: GH Research PLC
Filing Date: 2025-02-27
Form: 20-F
Item: Item 5
Chunk 86
---
 the costs of commercialization activities for GH001 and GH002 for any approved indications, or any other product candidate that receives regulatory approval to the extent such costs are not the responsibility of any
                                                future collaborators, including the costs and timing of establishing product sales, marketing, distribution, and manufacturing capabilities;                                            
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

•   subject to receipt of regulatory approval, revenue, if any, received from commercial sales of GH001 and GH002 and the respective medical devices for any approved indications or any other product candidates;
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

•   the extent to which we may in-license or acquire rights to other products, product candidates, medical devices or technologies;
-----------------------------------------------------------------------------------------------------------------------------------

•   our headcount growth and associated costs as we expand our research and development, increase our office space, and establish a commercial infrastructure;
--------------------------------------------------------------------------------------------------------------------------------------------------------------

•   the costs of preparing, filing and prosecuting patent applications and maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property-related claims;
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

•   the effect of competing product and market developments; and
----------------------------------------------------------------

•   the ongoing costs of operating as a public company.
-------------------------------------------------------
 
Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, convertible debt financings, strategic collaborations and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our existing shareholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of such existing shareholders. Debt financing, if available, may result in fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
 

  Table of Contents
If we raise funds through collaborations or marketing, distribution, licensing and royalty arrangements with third parties, we may have to relinquish valuable rights to our intellectual property or technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us or issue and sell our shares, which may result in dilution to our shareholders. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.